Genprex, Inc.
About Genprex, Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $0
- Net income
- -$16.2M
- Total assets
- $10.2M
- Market cap
- $6.8M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $6.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 29, 2018
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Genprex, Inc..